Form 4: 10x Genomics CEO Exercises Stock Options, Increases Holdings

10x Genomics CEO Serge Saxonov exercised stock options and acquired 12,000 shares of Class A Common Stock at $1.2 per share on December 23, 2024.

Summary

• Serge Saxonov, CEO of 10x Genomics, exercised stock options to acquire 12,000 shares of Class A Common Stock on December 23, 2024.
• The transaction was executed at a price of $1.2 per share.
• Following the transaction, Mr. Saxonov directly owns 884,574 shares of Class A Common Stock.
• Mr. Saxonov also indirectly owns shares through various trusts, including the Andromeda Trust (27 shares), Sirius Trust (870 shares), Y/S Descendants' Trust (213,250 shares), and Y/S Pot Trust (22,570 shares).
• The stock options exercised were part of an option grant that vested over time, with the final vesting date on October 1, 2021.

Sentiment

Score: 7

Explanation: The document reflects a routine insider transaction, which is generally viewed positively as it aligns management's interests with shareholders. There is no indication of any negative sentiment.

Positives

• The CEO's exercise of stock options demonstrates confidence in the company's future prospects.
• The acquisition of shares increases the CEO's stake in the company, aligning his interests with those of shareholders.

Industry Context

This is a standard SEC Form 4 filing, which is common for company insiders when they trade company stock. It provides transparency into the transactions of key personnel.

Comparison to Industry Standards

• Form 4 filings are a standard practice for publicly traded companies in the US, ensuring transparency of insider transactions.
• The transaction is similar to other executive stock option exercises seen across the industry.

Stakeholder Impact

• The transaction increases the CEO's stake in the company, which can be viewed positively by shareholders.

Key Dates

Keywords

stock options, insider trading, beneficial ownership, Form 4, 10x Genomics, TXG, Serge Saxonov, equity securities